Cargando…

A single-center experience with pancreatic cystic neuroendocrine tumors

BACKGROUND: Pancreatic neuroendocrine tumors (PNET) are rare, with a significant malignant potential. This study aimed to determine outcomes of patients with resected PNETs according to the cystic component and confirm the accuracy of preoperative staging. METHODS: From 1997 to 2016, 106 patients un...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalil, Ange, Ewald, Jacques, Marchese, Ugo, Autret, Aurélie, Garnier, Jonathan, Niccoli, Patricia, Piana, Gilles, Poizat, Flora, Giovannini, Marc, Delpero, Jean-Robert, Turrini, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429455/
https://www.ncbi.nlm.nih.gov/pubmed/32799893
http://dx.doi.org/10.1186/s12957-020-01994-6
_version_ 1783571266624552960
author Khalil, Ange
Ewald, Jacques
Marchese, Ugo
Autret, Aurélie
Garnier, Jonathan
Niccoli, Patricia
Piana, Gilles
Poizat, Flora
Giovannini, Marc
Delpero, Jean-Robert
Turrini, Olivier
author_facet Khalil, Ange
Ewald, Jacques
Marchese, Ugo
Autret, Aurélie
Garnier, Jonathan
Niccoli, Patricia
Piana, Gilles
Poizat, Flora
Giovannini, Marc
Delpero, Jean-Robert
Turrini, Olivier
author_sort Khalil, Ange
collection PubMed
description BACKGROUND: Pancreatic neuroendocrine tumors (PNET) are rare, with a significant malignant potential. This study aimed to determine outcomes of patients with resected PNETs according to the cystic component and confirm the accuracy of preoperative staging. METHODS: From 1997 to 2016, 106 patients underwent resection of PNETs, including 73 purely solid (S-PNETs, 69%), 21 mixed (M-PNETs, 20%), and 12 purely cystic lesions (C-PNETs, 11%). To ensure consistent comparisons of overall (OS) and disease-free (DFS) survival outcomes between the 3 groups, the patients were matched according to the World Health Organization (WHO) grade and tumor height. RESULTS: Overall, the rate of correlation between the preoperative and pathological diagnoses was low in the C-PNET group (33%, P = 0.03). None of the 24 patients (23%) with metastatic disease at the time of surgery were in the C-PNET group. Furthermore, significantly more parenchyma-sparing resections (P = 0.039) and fewer enlarged resections (P = 0.019) were achieved in the C-PNET group. C-PNET group had a significantly lower node invasion rate than the S-PNET and M-PNET groups (8% vs. 41% and 24%, P = 0.004). Although median OS was comparable in all 3 groups before (P = 0.3) and after (P = 0.18) matching, higher median DFS was observed in the C-PNET group than in the other groups after matching (P = 0.038). CONCLUSION: C-PNET was associated with a better prognosis than PNET with a solid component. The results support a wait-and-see policy in cases wherein a reliable preoperative diagnosis remains challenging.
format Online
Article
Text
id pubmed-7429455
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74294552020-08-18 A single-center experience with pancreatic cystic neuroendocrine tumors Khalil, Ange Ewald, Jacques Marchese, Ugo Autret, Aurélie Garnier, Jonathan Niccoli, Patricia Piana, Gilles Poizat, Flora Giovannini, Marc Delpero, Jean-Robert Turrini, Olivier World J Surg Oncol Research BACKGROUND: Pancreatic neuroendocrine tumors (PNET) are rare, with a significant malignant potential. This study aimed to determine outcomes of patients with resected PNETs according to the cystic component and confirm the accuracy of preoperative staging. METHODS: From 1997 to 2016, 106 patients underwent resection of PNETs, including 73 purely solid (S-PNETs, 69%), 21 mixed (M-PNETs, 20%), and 12 purely cystic lesions (C-PNETs, 11%). To ensure consistent comparisons of overall (OS) and disease-free (DFS) survival outcomes between the 3 groups, the patients were matched according to the World Health Organization (WHO) grade and tumor height. RESULTS: Overall, the rate of correlation between the preoperative and pathological diagnoses was low in the C-PNET group (33%, P = 0.03). None of the 24 patients (23%) with metastatic disease at the time of surgery were in the C-PNET group. Furthermore, significantly more parenchyma-sparing resections (P = 0.039) and fewer enlarged resections (P = 0.019) were achieved in the C-PNET group. C-PNET group had a significantly lower node invasion rate than the S-PNET and M-PNET groups (8% vs. 41% and 24%, P = 0.004). Although median OS was comparable in all 3 groups before (P = 0.3) and after (P = 0.18) matching, higher median DFS was observed in the C-PNET group than in the other groups after matching (P = 0.038). CONCLUSION: C-PNET was associated with a better prognosis than PNET with a solid component. The results support a wait-and-see policy in cases wherein a reliable preoperative diagnosis remains challenging. BioMed Central 2020-08-15 /pmc/articles/PMC7429455/ /pubmed/32799893 http://dx.doi.org/10.1186/s12957-020-01994-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Khalil, Ange
Ewald, Jacques
Marchese, Ugo
Autret, Aurélie
Garnier, Jonathan
Niccoli, Patricia
Piana, Gilles
Poizat, Flora
Giovannini, Marc
Delpero, Jean-Robert
Turrini, Olivier
A single-center experience with pancreatic cystic neuroendocrine tumors
title A single-center experience with pancreatic cystic neuroendocrine tumors
title_full A single-center experience with pancreatic cystic neuroendocrine tumors
title_fullStr A single-center experience with pancreatic cystic neuroendocrine tumors
title_full_unstemmed A single-center experience with pancreatic cystic neuroendocrine tumors
title_short A single-center experience with pancreatic cystic neuroendocrine tumors
title_sort single-center experience with pancreatic cystic neuroendocrine tumors
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429455/
https://www.ncbi.nlm.nih.gov/pubmed/32799893
http://dx.doi.org/10.1186/s12957-020-01994-6
work_keys_str_mv AT khalilange asinglecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT ewaldjacques asinglecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT marcheseugo asinglecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT autretaurelie asinglecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT garnierjonathan asinglecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT niccolipatricia asinglecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT pianagilles asinglecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT poizatflora asinglecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT giovanninimarc asinglecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT delperojeanrobert asinglecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT turriniolivier asinglecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT khalilange singlecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT ewaldjacques singlecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT marcheseugo singlecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT autretaurelie singlecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT garnierjonathan singlecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT niccolipatricia singlecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT pianagilles singlecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT poizatflora singlecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT giovanninimarc singlecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT delperojeanrobert singlecenterexperiencewithpancreaticcysticneuroendocrinetumors
AT turriniolivier singlecenterexperiencewithpancreaticcysticneuroendocrinetumors